LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | PI103 | 10 | uM | LJP6 | 1 | I13 | 72 | hr | 1694 | 2370 | 11220 | 0.2112 | 0.1310 |
MCF 10A | PI103 | 10 | uM | LJP6 | 2 | I13 | 72 | hr | 1694 | 2283 | 11309 | 0.2019 | 0.1151 |
MCF 10A | PI103 | 10 | uM | LJP6 | 3 | I13 | 72 | hr | 1694 | 2028 | 11121 | 0.1824 | 0.0685 |
MCF 10A | Dovitinib | 0.04 | uM | LJP5 | 1 | E24 | 72 | hr | 1694 | 10354 | 11042 | 0.9377 | 0.9530 |
MCF 10A | Dovitinib | 0.04 | uM | LJP5 | 2 | E24 | 72 | hr | 1694 | 10245 | 11099 | 0.9230 | 0.9418 |
MCF 10A | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 1694 | 10500 | 11168 | 0.9402 | 0.9552 |
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 1694 | 9247 | 11042 | 0.8374 | 0.8730 |
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 1694 | 9540 | 11099 | 0.8595 | 0.8914 |
MCF 10A | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 1694 | 9954 | 11168 | 0.8913 | 0.9172 |
MCF 10A | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 1694 | 7437 | 11042 | 0.6735 | 0.7280 |
MCF 10A | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 1694 | 6784 | 11099 | 0.6112 | 0.6680 |
MCF 10A | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 1694 | 7063 | 11168 | 0.6324 | 0.6900 |
MCF 10A | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1694 | 5232 | 11042 | 0.4738 | 0.5173 |
MCF 10A | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 1694 | 5788 | 11099 | 0.5215 | 0.5731 |
MCF 10A | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1694 | 5107 | 11168 | 0.4573 | 0.5001 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1694 | 2869 | 11042 | 0.2598 | 0.2150 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 1694 | 2789 | 11099 | 0.2513 | 0.2018 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1694 | 2916 | 11168 | 0.2611 | 0.2209 |
MCF 10A | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 1694 | 1897 | 11042 | 0.1718 | 0.0427 |
MCF 10A | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 1694 | 1965 | 11099 | 0.1770 | 0.0562 |
MCF 10A | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 1694 | 1899 | 11168 | 0.1700 | 0.0428 |
MCF 10A | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 1694 | 11293 | 11042 | 1.0227 | 1.0167 |
MCF 10A | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 1694 | 11084 | 11099 | 0.9986 | 0.9990 |
MCF 10A | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 1694 | 11469 | 11168 | 1.0269 | 1.0196 |
MCF 10A | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 1694 | 11208 | 11042 | 1.0150 | 1.0110 |